Stock report · Delisted · Nasdaq
Kineta, Inc. (KANT)
0.34USD Delisted Final close · Jun 27, 2025
KANT no longer trades. Kineta was delisted from the Nasdaq in June 2025.
All prices on this page are historical. The last trade was on June 27, 2025, at $0.34.
KANT stock price history
Final trading statistics
- Final close
- $0.34
- Final trading day
- Jun 27, 2025
- Market cap at delisting
- $4.12M
- Shares outstanding
- 12.27M
- Final 52-week range
- $0.18 – $1.15
- Avg. volume (final 3 mo.)
- 15,614
- All-time high
- $8.33 · Feb 2023
- All-time low
- $0.09 · Aug 2019
- Return since IPO
- -64.6%
- Beta
- -3.66
- Book value / share
- −$0.79
- Price / book
- -0.42
About Kineta, Inc.
Kineta was a clinical-stage biotechnology company in the U.S. focused on immunotherapies. Its main cancer program was KVA12123, an antibody that blocks VISTA, given by infusion twice a week. It was in a Phase 1/2 trial, alone and combined with pembrolizumab, in patients with advanced solid tumors such as lung, ovarian, kidney, head and neck, and colorectal cancers.
The company was also developing an anti-CD27 agonist antibody meant to address exhausted T cells. It had collaboration and license deals with MSD International Business GmbH, Genentech, Merck & Co., FAIR Therapeutics and GigaGen.
Kineta was based in Mercer Island, Washington. Its shares were removed from the Nasdaq in June 2025, with the last trade on June 27, 2025 at $0.34.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Mercer Island, WA
- Employees
- 4
- IPO date
- February 11, 2016
- Delisted
- June 27, 2025
- SEC CIK
- 1479365
Kineta financials before the delisting
The last 4 fiscal years Kineta reported as a public company, fiscal year ending December.
KANT revenue and net income
KANT earnings per share
KANT annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $5.44M | −$14.1M | −$1.54 |
| FY2022 | $1.04M | −$63.4M | — |
| FY2021 | $9.09M | −$11.8M | — |
| FY2020 | $10.49M | −$8.1M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
Kineta stock FAQ
What happened to Kineta stock?
Kineta was delisted from the Nasdaq in June 2025. The final close was $0.34 on June 27, 2025.
Can I still buy KANT stock?
No. KANT is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on June 27, 2025.
What was the last price of KANT?
KANT last closed at $0.34 on June 27, 2025, which valued the company at about $4.12M.
How did Kineta do in its last full fiscal year?
In fiscal 2023, its last full year as a public company, Kineta reported revenue of $5.44M and net income of −$14.1M.
When did Kineta go public?
Kineta shares started trading on February 11, 2016.
KANT no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.